Chinese Journal of Pharmacovigilance ›› 2018, Vol. 15 ›› Issue (7): 440-440.
Previous Articles Next Articles
CHEN Fang, CUI Min*
Received:
2018-08-08
Revised:
2018-08-08
Online:
2018-07-20
Published:
2018-08-08
CLC Number:
CHEN Fang, CUI Min*. One Case of Anaphylactic Shock Induced by Dextran Iron Injection[J]. Chinese Journal of Pharmacovigilance, 2018, 15(7): 440-440.
Add to citation manager EndNote|Ris|BibTeX
[1] 旷满华, 熊问婧, 谢新鑫, 等. 不同口服铁剂治疗儿童缺铁性贫血安全性的网络Meta分析[J].中华疾病控制杂志, 2016, 20(10):1047-1052. [2] Reed J, Charytan C, Yee J.The safety of intravenous iron sucrose use in the elderly patient[J]. Consult Pharm, 2007, 22(3):230-238. [3] 苏慧, 周丽莹, 赵桂燕. 右旋糖酐铁肌注致全身过敏及局部坏死5例分析[J]. 中国医院药学杂志, 2008, 28(12):1049-1050. [4] Behera V,Chauhan R, Sinha S, et al.Anaphylactic Shock Secondary to Intravenous Iron Sucrose in Chronic Kidney Disease[J]. Indian J Hematol Blood Transfus, 2015, 31(3):391-393. [5] 程春雷, 范怡云, 祝清芬, 等. 右旋糖酐铁注射液不良反应文献分析[J].中国药业, 2013, 22(8):79-80. [6] Van Wyck D B, Marten M G, Seid M H, et al. Intravenous ferric carboxymaltose compared with oral iron in the treatment of post- partum anemia: a randomized controlled trial[J]. Obstet Gynecol, 2007, 110(2):267-278. [7] 任贻军, 张宏琳. 右旋糖酐铁注射液的少见不良反应[J]. 海峡药学, 2009, 21(8):202-204. [8] Faich G, Strobos J.Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans[J]. Am J Kidney Dis, 1999, 33(3):464-470. [9] Kortenhorst M S, Harmsze A M, Hasaart T H.Anaphylaxis after iron dextran administration in a pregnant woman[J]. Ned Tijdschr Geneeskd, 2012, 156(48):A5264. [10] Wang C, Graham D J, Kane RC, et al.Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron Products[J]. JAMA, 2015, 314(19):2062-2068. [11] 袁丽, 杨悦. 药品不良反应/事件之“严重(Serious)”与“重度(Severe)”的界定研究[J]. 中国药物警戒, 2016, 14(8):484-488. |
[1] | LI Xinying, BAO Lei, LI Shuran, ZHAO Ronghua, SUN Jing, XIE Dan, BAO Yanyan, GUO Shanshan, CUI Xiaolan, GENG Zihan. Effect of Shufeng Jiedu Capsules on the Production of Specific Antibodies against Influenza A H1N1 Virus and the Mechanisms [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 841-850. |
[2] | WANG Xinwei, PENG Yifeng, SUN Jing, JI Zuen, BAO Lei, LUO Henglei, GENG Zihan, ZHANG Hujuan, LI Shuran, ZHANG Jingsheng, GUO Shanshan, CUI Xiaolan, ZHAO Ronghua. Effect of Yiye Anti-Influenza Capsules on Pneumonia Induced by Human Coronavirus 229E Infection in Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 851-855. |
[3] | XIE Rui, SUN Qiyue, LI Yanying, ZHANG Jingsheng, ZHAO Ronghua, GUO Shanshan, GENG Zihan, BAO Lei, GAO Shuangrong, CUI Xiaolan, XIE Dan, SUN Jing. Impacts of Shuangshenling Granules on a Cadmium-Induced Chronic Renal Failure Model of Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 856-862. |
[4] | CHEN Siying, DING Xueli, LIU Shujia, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian. Modeling for Prediction of Cardiotoxicity of Chinese Herbal Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 869-875. |
[5] | CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing. Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882. |
[6] | ZHENG Haiyun, WANG Zhigang, WU Hongwei, WANG Shaonan, WANG Bin. Identification of in vitro and in vivo Chemical Constituents of Buxin Anmian Decoction Based on UPLC-Q Exactive Orbitrap HRMS [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 883-888. |
[7] | SUN Ya, WANG Xu, SUN Zhi, ZHOU Yubing. Dose Analysis of Linezolid in Severe Patients with Sepsis Complicated with Acute Kidney Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 889-895. |
[8] | SHI Qi, WANG Jianxin, WANG Guijie, LU Yueyang, ZHU Jiaxu, GAO Rui. Adjuvant Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Qingqi Huatan Pills: a Systematic Review [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 914-919. |
[9] | YING Jie, XU Xiaolong, LI Bo, LIU Tengwen, LIU Qingquan. Clinical Applications of Jinhua Qinggan Granules in the Treatment of Mild Influenza: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 920-923. |
[10] | KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927. |
[11] | LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932. |
[12] | LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji. Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936. |
[13] | ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing. Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940. |
[14] | ZHOU Yujie, HUANG Xiaojing, CHEN Mingyue, DU Pengqiang, WANG Aifeng. Two Cases of Severe Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 941-943. |
[15] | CHEN Huabao, LIU Wei, JIANG Ting, ZHENG Lingli, LI Jing. One Case of Acute Withdrawal Syndrome Caused by Naloxone [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 944-946. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||